<DOC>
	<DOCNO>NCT01199081</DOCNO>
	<brief_summary>Primary Objective : - Explore Dronedarone active metabolite pharmacokinetic ( PK ) profile accord different timing Dronedarone initiation . Secondary Objective : - Explore potential PK interaction Dronedarone Amiodarone - Evaluate rate Atrial Fibrillation ( AF ) recurrence study period ( randomization 60 day ) - To assess safety change Amiodarone Dronedarone Dronedarone safety</brief_summary>
	<brief_title>Pharmacokinetics Optimal Timing Dronedarone Initiation Following Long-term Amiodarone Patients With Paroxysmal Persistent Atrial Fibrillation</brief_title>
	<detailed_description>The maximum study duration per patient 10 week</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Screening : Paroxysmal persistent AF receive least 6 month amiodarone screen least last 2 month regimen 200 mg/day ( least 5 day per week ) prior screen Requiring change amiodarone treatment whatever reason , without liver , lung thyroid toxicity relate previous use amiodarone At least one cardiovascular risk factor ( i.e . age &gt; 70 , hypertension , diabetes , prior cerebrovascular disease leave atrial diameter &gt; = 50 mm Effective anticoagulation treatment verify International Normalized Ratio ( INR ) ( target INR &gt; 2 ) QTc Bazett &lt; 500 m 12lead ECG Randomization : Outpatients Inpatients ( except patient hospitalized screening period SAE ) Sinus rhythm Effective oral anticoagulation treatment verify INR ( target INR &gt; 2 ) . INR closely monitor initiate dronedarone patient take vitamin K antagonist per label QTc Bazett &lt; 500 m PR &lt; 280 m 12lead ECG Exclusion criterion : Screening : Contraindication oral anticoagulation Acute condition know cause AF Permanent AF Bradycardia &lt; 50 bpm rest 12lead ECG History , current heart failure leave ventricular systolic dysfunction Unstable hemodynamic condition Severe hepatic impairment WolffParkinsonWhite Syndrome Previous catheter ablation atrial fibrillation catheter ablation schedule next 10 week Previous history Amiodarone intolerance toxicity History thyroid dysfunction Mandatory contraindicate concomitant treatment : potent cytochrome P450 ( CYP3A4 ) inhibitor drug herbal product prolong QT interval know increase risk Torsade de Pointes Previous treatment class I class III antiarrhythmic drug ( include sotalol ) amiodarone antiarrhythmic drug take less one week day screening ( take one week screening , patient include ) Randomization Bradycardia &lt; 50 bpm 12lead ECG History , current heart failure leave ventricular systolic dysfunction Unstable hemodynamic condition Severe hepatic impairment Mandatory contraindicate concomitant treatment : potent cytochrome P450 ( CYP3A4 ) inhibitor drug herbal product prolong QT interval know increase risk Torsade de Pointes The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>